QCQuangang Chen

Quangang Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Quangang Chen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microenvironment-responsive ellagic acid-histidine-iron carbon-dot induces ferroptosis in HepG2 cells by disrupting iron and redox homeostasis

    by Wei Chen, Xianfeng Zhan, Pengkai Xu, PengFei Wu, Xueyi Feng, Chengbin Shi, Haiquan Li, Quangang Chen, Yaoxin Yang, Fubao Liu

    Hepatocellular carcinoma (HCC) represents a clinically challenging malignancy, for which existing therapeutic modalities still face substantial limitations. Ellagic acid, a naturally occurring polyphenol with anticancer potential against HCC, nevertheless suffers from notable intrinsic physicochemical drawbacks that restrict its direct therapeutic application. Here, we developed an ellagic acid-histidine-iron carbon-dot nanozyme (EA-His-Fe-CDs) through a one-pot hydrothermal route. EA-His-Fe-CDs formed dispersed sub-10-nm particles containing redox-active iron and remained colloidally stable in physiologically relevant media. The material exhibited acidity-enhanced iron release, glutathione (GSH) consumption, and hydroxyl-radical generation, establishing a microenvironment-responsive catalytic profile. In HepG2 cells, EA-His-Fe-CDs more effectively suppressed viability, DNA synthesis, and migration-associated wound closure than EA, EA-CDs, or EA-Fe-CDs. Increasing exposure elevated reactive oxygen species (ROS) and labile iron, depolarized mitochondrial membranes, depleted cellular antioxidant capacity, and promoted lipid peroxidation. These responses were accompanied by suppression of the SLC7A11/GSH/GPX4 defense axis, altered TFR1 and FTH1 expression, increased ACSL4 and ALOX15, and attenuation of Nrf2/HO-1 signaling. GSH replenishment and ferrostatin-1 rescued the cellular phenotype at distinct mechanistic levels, supporting a lipid-peroxidation-dependent ferroptotic mechanism associated with iron dysregulation rather than nonspecific oxidative injury. Collectively, EA-His-Fe-CDs integrate responsive iron mobilization with antioxidant disruption to induce ferroptosis in hepatocellular carcinoma cells.

  • Open Access

    Coronavirus Nsp5‑mediated dual‑site cleavage of GSDMA modifies its antiviral and proinflammatory functions

    by Chenyu Li, Yuxi Zhao, Yuchen Zhang, Shuai Li, Longfei Chen, Xiangfei Xu, Tong Ding, Yuanqing Wang, Xiang Gao, Zhaoyu Lin, et al.

    Although Gasdermin A (GSDMA) drives inflammation by inducing pyroptosis, its specific role in antiviral defense remains unclear. Here we identify GSDMA as an immunomodulatory protein activated in response to coronavirus (CoV) infection. Specifically, CoV-encoded protease nsp5 cleaves GSDMA at two conserved glutamine sites, Q247 and Q187. Cleavage at Q247 liberates an active N-terminal fragment (GSDMA_1–247) that triggers pyroptosis, promotes inflammation, and restricts viral replication. In contrast, cleavage at the alternative site Q187 attenuates this function. Using Gsdma -/- mice, we show that GSDMA deficiency increases viral loads but reduces inflammation, tissue damage, and mortality upon infection. These findings suggest that disease severity is driven more by inflammation than by viral load. Our findings reveal a novel mechanism of antiviral immunity and inflammatory regulation via CoV nsp5-mediated dual cleavage of GSDMA, highlighting a potential target for combined antiviral and anti-inflammatory therapies.

  • Open Access

    Single-cell RNA sequencing analysis reveals a novel porcine alveolar macrophage subtype with high SLAMF7 expression promoting PRRSV infection

    by Ankang Hu, Yao Guo, Yusi Zhou, Piao Chen, Yuhua Zhu, Tingjun Liu, Lianlian Wu, Dandan Qiao, Zhutao Huang, Yang Chen, et al.

    Porcine reproductive and respiratory syndrome virus (PRRSV) is a major and highly contagious swine pathogen that severely impacts the global pork industry. Typically, porcine alveolar macrophages (PAM) isolated from pigs and infected with PRRSV are used to analyze viral pathogenesis, although it remains unclear whether it accurately reflects the in vivo disease process. In this study, scRNA-seq analysis revealed distinct transcriptional profiles between in vitro-cultured and freshly isolated PAMs. Inflammation, apoptosis, autophagy, and the TNF signal pathway were activated both in vivo and in vitro, however, only partial enriched GO terms and KEGG pathways were coincidental. Notably, PRRSV genomes were detected in the T and B cells in vivo, indicating a potential effect of PRRSV on T and B cell function. Results also showed that although PRRSV infection triggered robust inflammation, only a minority of PAMs were infected. Interestingly, bystander cells displayed similar inflammatory responses to those of PRRSV-infected cells, hinting at the role bystander cells play in the inflammatory response. Through scRNA-seq analysis, transcriptomic profiling of cells pre- and post-PRRSV infection revealed several distinct subclusters (S0-S7 and SS0-SS6), with the S5 subpopulation exhibiting the highest PRRSV infection rate and the SS6 subpopulation showing the fastest PRRSV replication rate. The SLAMF7 gene emerged as a key gene in these two subpopulations infected with PRRSV. Knockdown of SLAMF7 significantly reduced PRRSV infection and suppressed PRRSV-induced inflammation, while its overexpression promoted replication of PRRSV and inflammation induced by PRRSV.


  • Open Access

    Pan-cancer analysis shows that TRIP13 as a potential prognostic and immunotherapeutic biomarker for multiple cancer types including LIHC and LUAD

    by Chong Li, Ziyu Bd Zhou, Yi Mm Liu, Yao Guo, Tingjun Liu, Jie Teng, Piao Chen, Ankang Hu, Lianlian Wu, Dandan Qiao, et al.

    Growing evidence indicates that thyroid hormone receptor interactor 13 (TRIP13) plays an oncogenic role in various malignancies. Pan-cancer analysis was performed to elucidate the prognostic value and oncogenic role of TRIP13, and detect TRIP13 expression levels in diverse cancer types. We found that TRIP13 was overexpressed in multiple tumors. Subsequently, we explored the relationship between TRIP13 expression-associated alterations and clinical prognosis, DNA methylation, immune cell infiltration, immune checkpoints, tumor mutational burden, microsatellite instability, and drug sensitivity. Gene set enrichment analysis was utilized to explore the molecular mechanism of TRIP13. A nomogram was developed to predict the impact of TRIP13 expression on an liver hepatocellular carcinoma prognosis. The miRDB database was used to predict miRNA targets for TRIP13. The results indicated that TRIP13 overexpression was associated with a poor overall survival, disease-specific survival, and progression-free interval in various cancer types. The mutation frequency of TRIP13 was the highest in individuals with lung squamous cell carcinoma. TRIP13 expression levels were negatively associated with immunocyte infiltration, immune scores, tumor mutational burden, microsatellite instability, and DNA methylation in certain cancers, and positively correlated with the expression of at least 5 immune checkpoint-related genes in bladder carcinoma, breast cancer, kidney clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, mesothelioma, and thyroid cancer. In addition, we discovered that TRIP13 participated in the cell cycle during Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis for most cancers. The areas under the curve for the 1-, 3-, and 5-year survival rates in the nomogram exceeded 0.6, indicating that the model has good predictive performance, and was validated using samples obtained from liver hepatocellular carcinoma patients. We also found that miR-656-3p tends to bind to TRIP13 mRNA and regulate TRIP13 expression. Additionally, we identified 26 drugs sensitive to tumors with high TRIP13 expression levels from the CTRP and GDSC databases. Finally, the promoting effect of TRIP13 on lung cancer was verified, the results demonstrating TRIP13 could accelerate lung cancer cell proliferation, migration, and invasion. Collectively, our findings suggest that TRIP13 may act as a potential prognostic marker and novel target for cancer therapy.


  • Open Access

    Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study

    by Tingjun Mm Liu, Lianlian Mm Wu, Jing Mm Liu, Hao Mm Chen, Bao Zhu, Dandan Mm Qiao, Yuhua Mm Zhu, Quangang Chen, Ankang Hu

    Lung adenocarcinoma (LUAD) is a non-small-cell lung cancer and is the leading cause of cancer-related deaths worldwide. Immunotherapy is a promising candidate for LUAD, and tumor mutation burden (TMB) could be a new biomarker to monitor the response of cancer patients to immunotherapy. It is known that the mucin 16 (MUC16) mutation is the most common and affects the progression and prognosis of several cancers. However, whether MUC16 mutations are associated with TMB and tumor-infiltrating immune cells in LUAD is not fully elucidated. All the data were obtained from the cancer genome atlas database to assess the prognostic value and potential mechanism of MUC16 in LUAD. An immune prognostic model (IPM) was developed based on immune-related genes that could be differentially expressed between MUC16MUT and MUC16WT LUAD patients. Later, the IPM effect on the prognosis and immunotherapy of LUAD was comprehensively evaluated. MUC16 was frequently mutated in LUAD, with a mutational frequency of 43.4%, significantly associated with higher TMB and better clinical prognosis. Based on 436 patients with LUAD, an IPM was established and validated to differentiate patients with a low or high risk of poor survival. The univariate and multivariate Cox regression analyses demonstrated that the IPM was an independent prognostic indicator for LUAD patients. Elevated expressions of PD-L1, LAG3, PDCD1, and SIGLEC15, and most of the T-effector and interferon-γ gene signatures, were depicted in the high-risk group. Moreover, the nomogram using the IPM and clinical prognostic factors also predicted the overall survival and clinical utility. Our project developed a robust risk signature depending on the MUC16 status and provided novel insights for individualized treatment options for LUAD patients.


  • Open Access

    Comprehensive analysis identifies DNA damage repair-related gene HCLS1 associated with good prognosis in lung adenocarcinoma

    by Tingjun Liu, Ankang Hu, Hao Chen, Yan Li, Yonghui Wang, Yao Guo, Tingya Liu, Jie Zhou, Debao Li, Quangang Chen

    Background: Lung cancer is the leading cause of cancer-associated mortality. Lung adenocarcinoma (LUAD) amounts to more than 40% of all lung malignancies. Therefore, developing clinically useful biomarkers for this disease is critical. DNA damage repair (DDR) is a complicated signal transduction process that ensures genomic stability. DDR should be comprehensively analyzed to elucidate their clinical significance and tumor immune microenvironment interactions. Methods: In this study, DDR-related genes (DRGs) were selected to investigate their prognostic impact on LUAD. A regression-based prognostic model was established based on The Cancer Genome Atlas (TCGA)-LUAD cohort and three external Gene Expression Omnibus (GEO) validation cohorts (GSE31210, GSE68465, and GSE72094). The robust, established model could independently predict the clinical outcomes in patients. Then, the prognostic performance of risk profiles was assessed using a time-dependent receiver operating characteristic (ROC) curve, Cox regression, nomogram, and Kaplan-Meier analyses. Furthermore, the potential biological functions and infiltration status of DRGs in LUAD were investigated with ESTIMATE and CIBERSORT. Finally, the effects of HCLS1 on the clinical features, prognosis, biological function, immune infiltration, and treatment response in LUAD were systematically analyzed. Results: Eleven DRGs were constructed to categorize patients into high- and low-risk groups. The risk score was an independent predictor of overall survival (OS). HCLS1 expression was downregulated in LUAD samples and linked with clinicopathological features. Multivariate Cox regression analysis using the Kaplan-Meier plotter revealed that low HCLS1 expression was independently associated with poor OS. Moreover, the HCLS1 high-expression group had higher immune-related gene expression and ESTIMATE scores. It was positively correlated with the infiltration of M1 macrophages, activated memory CD4 T cells, CD8 T cells, memory B cells, resting dendritic cells, and memory CD4 T cells, Tregs, and neutrophils. Conclusions: A new classification system was developed for LUAD according to DDR characteristics. This stratification has important clinical values, reliable prognosis, and immunotherapy in patients with LUAD. Moreover, HCLS1 is a potential prognostic biomarker of LUAD that correlates with the extent of immune cell infiltration in the tumor microenvironment (TME).


  • Open Access

    In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma

    by Ankang Hu, Kaicheng Bs Tang, Jing Mm Liu, Xufeng Han, Quangang Chen

    Lung adenocarcinoma (LUAD) is a common lung cancer. Although there are various treatments for LUAD, its prognosis remains poor. Therefore, it is imperative to identify new targets and develop novel therapeutic strategies. In this study, we analyze the expression of proline rich 11 (PRR11) in pan cancer based on The Cancer Genome Atlas (TCGA) database, and explore the prognostic value of PRR11 in LUAD by GEPIA2 (Gene Expression Profiling Interactive Analysis, version 2) database. In addition, the relationship between PRR11 and the clinicopathological features of LUAD was analyzed using UALCAN database. The association between PRR11 expression and immune infiltration was accessed. The PRR11 related genes were screened using LinkOmics and GEPIA2. Gene Ontology Term Enrichment (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was performed by David database. The results suggested that the expression of PRR11 in most tumor tissues was significantly higher than that in normal tissues. In LUAD patients, high expression of PRR11 was associated with shortened first progression survival (FPS), overall survival (OS) and post progression survival (PPS), and correlated with individual cancer stage, race, gender, smoking habit, and tissue subtype. Besides, the high expression of PRR11 was accompanied by a relatively higher infiltration level of cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cell (MDSC), and decreased infiltration level of CD8+ T cells in the tumor microenvironment. GO analyses showed that PRR11 participated in biological processes such as cell division and cell cycle, and was involved in protein binding and microtubule binding functions. KEGG analyses revealed that PRR11 was implicated in p53 signaling pathway. All the results indicated that PRR11 might be an independent prognostic biomarker and therapeutic target for LUAD.


  • Open Access

    Discovery of rafoxanide as a novel agent for the treatment of non-small cell lung cancer

    by Ankang Hu, Jing Liu, Yonghui Wang, Maoyin Zhang, Yao Guo, Ying Qin, Tingya Liu, Yanjuan Men, Quangang Chen, Tingjun Liu

    Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases, is associated with a poor outcome. Rafoxanide is an anthelmintic drug that inhibits tumor growth in certain malignancies. However, its impact on NSCLC remains unknown. In this study, we examined the effect of rafoxanide on NSCLC and dissected the underlying mechanism. The results showed that rafoxanide significantly inhibited the growth, invasion, and migration of NSCLC cells. Besides, rafoxanide can induce NSCLC cell apoptosis and cell cycle arrest in a dose-dependent manner. RNA-seq analysis revealed that genes associated with endoplasmic reticulum stress (ER) stress responses were activated. Mechanistically, we found Rafoxanide can induce ER stress and activate the unfolded protein response (UPR). Apoptosis was activated by excessive ER stress, and autophagy was activated to partially alleviate ER stress. In vivo, we found that rafoxanide inhibited the growth of A549 and H1299 xenograft mouse models without severe side effects. Collectively, the present study indicates that rafoxanide may be a candidate drug for the treatment of NSCLC.


  • Open Access

    Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

    by Ankang Hu, Yonghui Wang, Jiahao Tian, Zihan Chen, Renjin Chen, Xufeng Han, Yang Chen, Tingjun Liu, Quangang Chen

    Background: DExD-box helicase 21 (DDX21) is an essential member of the RNA helicase family. DDX21 is involved in the carcinogenesis of various malignancies, but there has been no comprehensive research on its involvement in different types of cancer.Method: This study used TCGA, CPTAC, GTEx, GEO, FANTOM5, BioGRID, TIMER2, GEPIA2, cBioPortal, STRING, and Metascape databases and Survival ROC software to evaluate DDX21 gene expression, protein expression, immunohistochemistry, gene mutation, immune infiltration, and protein phosphorylation in 33 TCGA tumor types, as well as the prognostic relationship between DDX21 and different tumors, by survival analysis and similar gene enrichment analysis. Furthermore, Cell Counting Kit-8 (CCK-8) and Transwell studies were employed to assess the effect of DDX21 expression on lung adenocarcinoma (LUAD) cell proliferation and migration.Result: The DDX21 gene was highly expressed in most cancers, and overexpression was associated with poor overall survival (OS) and disease-free survival (DFS). DDX21 mutations were most common in uterine corpus endometrial carcinoma (UCEC; >5%), and DDX21 expression was positively correlated with the degree of infiltration of CAF and CD8+ cells in several tumor types. Numerous genes were co-expressed with DDX21. Gene enrichment analysis revealed close links between DDX21, RNA metabolism, and ribosomal protein production. In vitro analysis of LUAD cells showed that DDX21 expression was positively correlated with cell proliferation and migration capacity, consistent with prior bioinformatics studies.Conclusions: DDX21 is overexpressed in a variety of cancers, and overexpression in some cancers is associated with poor prognosis. Immune infiltration and DDX21-related gene enrichment analyses indicated that DDX21 may affect cancer development through mechanisms that regulate tumor immunity, RNA metabolism, and ribosomal protein synthesis. This pan-cancer study revealed the prognostic value and the oncogenic role of DDX21.